Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dominic Clarke

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Eye (London, England)|February 9, 2022
First year of implementing OCT into a diabetic eye screening service-quantification of the reduction in hospital eye service referralsSarah Meredith, Spyridon Mourtzoukos, Christina Rennie, et al.
Veterinary Pathology|July 26, 2024
Meningoencephalomyelitis and brachial plexitis in a dog infected with louping ill virusSai Fingerhood, Karen L Mansfield, Arran J Folly, et al.
Cytotherapy|November 25, 2015
Current perspectives on the use of ancillary materials for the manufacture of cellular therapiesJennifer Solomon, Lynn Csontos, Dominic Clarke, et al.
Technology in Cancer Research & Treatment|March 23, 2007
Development of a tissue engineered human prostate tumor equivalent for use in the evaluation of cryoablative techniquesAnthony T Robilotto, Dominic Clarke, John M Baust, et al.
Cytotherapy|December 18, 2024
Particulates in CGT guidance survey results - an ISCT process development & manufacturing committee perspective on cell and gene therapy industry knowledge awarenessNisha Durand, Lindsay Davies, Stephanie Davies, et al.
Cytotherapy|June 1, 2022
Impact considerations of post-production processes on cell and gene drug productsJohn Fink, Michael Scott, Sebastian Rieck, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|January 31, 2023
Performance of an artificial intelligence automated system for diabetic eye screening in a large English populationSarah Meredith, Mark van Grinsven, Jonne Engelberts, et al.
Cytotherapy|July 28, 2020
Transitioning from development to commercial: risk-based guidance for critical materials management in cell therapiesMichael Scott, Dominic Clarke, Yonatan Lipsitz, et al.
Cytotherapy|September 29, 2022
Particulates are everywhere, but are they harmful in cell and gene therapies?Samuel A Molina, Stephanie J Davies, Dalip Sethi, et al.
Cytotherapy|August 21, 2012
Managing particulates in cellular therapyDominic Clarke, Dorit Harati, Jerold Martin, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Eye (London, England)|February 9, 2022
First year of implementing OCT into a diabetic eye screening service-quantification of the reduction in hospital eye service referralsSarah Meredith, Spyridon Mourtzoukos, Christina Rennie, et al.
Veterinary Pathology|July 26, 2024
Meningoencephalomyelitis and brachial plexitis in a dog infected with louping ill virusSai Fingerhood, Karen L Mansfield, Arran J Folly, et al.
Cytotherapy|November 25, 2015
Current perspectives on the use of ancillary materials for the manufacture of cellular therapiesJennifer Solomon, Lynn Csontos, Dominic Clarke, et al.
Technology in Cancer Research & Treatment|March 23, 2007
Development of a tissue engineered human prostate tumor equivalent for use in the evaluation of cryoablative techniquesAnthony T Robilotto, Dominic Clarke, John M Baust, et al.
Cytotherapy|December 18, 2024
Particulates in CGT guidance survey results - an ISCT process development & manufacturing committee perspective on cell and gene therapy industry knowledge awarenessNisha Durand, Lindsay Davies, Stephanie Davies, et al.
Cytotherapy|June 1, 2022
Impact considerations of post-production processes on cell and gene drug productsJohn Fink, Michael Scott, Sebastian Rieck, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|January 31, 2023
Performance of an artificial intelligence automated system for diabetic eye screening in a large English populationSarah Meredith, Mark van Grinsven, Jonne Engelberts, et al.
Cytotherapy|July 28, 2020
Transitioning from development to commercial: risk-based guidance for critical materials management in cell therapiesMichael Scott, Dominic Clarke, Yonatan Lipsitz, et al.
Cytotherapy|September 29, 2022
Particulates are everywhere, but are they harmful in cell and gene therapies?Samuel A Molina, Stephanie J Davies, Dalip Sethi, et al.
Cytotherapy|August 21, 2012
Managing particulates in cellular therapyDominic Clarke, Dorit Harati, Jerold Martin, et al.
Pageof 3